These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 26810656)

  • 21. Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid.
    Li J; Tan Z; Tang S; Hewlett I; Pang R; He M; He S; Tian B; Chen K; Yang M
    Bioorg Med Chem; 2009 Apr; 17(8):3177-88. PubMed ID: 19328002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The HIV-1 capsid protein as a drug target: recent advances and future prospects.
    Domenech R; Neira JL
    Curr Protein Pept Sci; 2013 Dec; 14(8):658-68. PubMed ID: 24106962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication.
    Mukherjee S; Weiner WS; Schroeder CE; Simpson DS; Hanson AM; Sweeney NL; Marvin RK; Ndjomou J; Kolli R; Isailovic D; Schoenen FJ; Frick DN
    ACS Chem Biol; 2014 Oct; 9(10):2393-403. PubMed ID: 25126694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Roles of Capsid-Interacting Host Factors in Multimodal Inhibition of HIV-1 by PF74.
    Saito A; Ferhadian D; Sowd GA; Serrao E; Shi J; Halambage UD; Teng S; Soto J; Siddiqui MA; Engelman AN; Aiken C; Yamashita M
    J Virol; 2016 Jun; 90(12):5808-5823. PubMed ID: 27076642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein.
    Lemke CT; Titolo S; von Schwedler U; Goudreau N; Mercier JF; Wardrop E; Faucher AM; Coulombe R; Banik SS; Fader L; Gagnon A; Kawai SH; Rancourt J; Tremblay M; Yoakim C; Simoneau B; Archambault J; Sundquist WI; Mason SW
    J Virol; 2012 Jun; 86(12):6643-55. PubMed ID: 22496222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the Early Step of Building Block Organization in Viral Capsid Assembly.
    Lampel A; Bram Y; Ezer A; Shaltiel-Kario R; Saad JS; Bacharach E; Gazit E
    ACS Chem Biol; 2015 Aug; 10(8):1785-90. PubMed ID: 25997366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An in vitro fluorescence screen to identify antivirals that disrupt hepatitis B virus capsid assembly.
    Stray SJ; Johnson JM; Kopek BG; Zlotnick A
    Nat Biotechnol; 2006 Mar; 24(3):358-62. PubMed ID: 16474383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 Resistance to the Capsid-Targeting Inhibitor PF74 Results in Altered Dependence on Host Factors Required for Virus Nuclear Entry.
    Zhou J; Price AJ; Halambage UD; James LC; Aiken C
    J Virol; 2015 Sep; 89(17):9068-79. PubMed ID: 26109731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitors.
    Radi M; Falchi F; Garbelli A; Samuele A; Bernardo V; Paolucci S; Baldanti F; Schenone S; Manetti F; Maga G; Botta M
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2094-8. PubMed ID: 22300661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Equine Myxovirus Resistance Protein 2 Restricts Lentiviral Replication by Blocking Nuclear Uptake of Capsid Protein.
    Ji S; Na L; Ren H; Wang Y; Wang X
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29743377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity.
    Abdurahman S; Végvári A; Youssefi M; Levi M; Höglund S; Andersson E; Horal P; Svennerholm B; Balzarini J; Vahlne A
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3737-44. PubMed ID: 18644965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-activity relationships (SAR) research of thiourea derivatives as dual inhibitors targeting both HIV-1 capsid and human cyclophilin A.
    Chen K; Tan Z; He M; Li J; Tang S; Hewlett I; Yu F; Jin Y; Yang M
    Chem Biol Drug Des; 2010 Jul; 76(1):25-33. PubMed ID: 20456372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of the mode of action of a potent dengue virus capsid inhibitor.
    Scaturro P; Trist IM; Paul D; Kumar A; Acosta EG; Byrd CM; Jordan R; Brancale A; Bartenschlager R
    J Virol; 2014 Oct; 88(19):11540-55. PubMed ID: 25056895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 Maturation: Lessons Learned from Inhibitors.
    Kleinpeter AB; Freed EO
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32858867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel postentry inhibitor of human immunodeficiency virus type 1 replication screened by yeast membrane-associated two-hybrid system.
    Urano E; Kuramochi N; Ichikawa R; Murayama SY; Miyauchi K; Tomoda H; Takebe Y; Nermut M; Komano J; Morikawa Y
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4251-60. PubMed ID: 21746942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes.
    Lamorte L; Titolo S; Lemke CT; Goudreau N; Mercier JF; Wardrop E; Shah VB; von Schwedler UK; Langelier C; Banik SS; Aiken C; Sundquist WI; Mason SW
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4622-31. PubMed ID: 23817385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library.
    Wu G; Zalloum WA; Meuser ME; Jing L; Kang D; Chen CH; Tian Y; Zhang F; Cocklin S; Lee KH; Liu X; Zhan P
    Eur J Med Chem; 2018 Oct; 158():478-492. PubMed ID: 30243152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An insight on medicinal aspects of novel HIV-1 capsid protein inhibitors.
    Sun L; Zhang X; Xu S; Huang T; Song S; Cherukupalli S; Zhan P; Liu X
    Eur J Med Chem; 2021 May; 217():113380. PubMed ID: 33751981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.
    Urano E; Ablan SD; Mandt R; Pauly GT; Sigano DM; Schneider JP; Martin DE; Nitz TJ; Wild CT; Freed EO
    Antimicrob Agents Chemother; 2016 Jan; 60(1):190-7. PubMed ID: 26482309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biophysical analysis of the MHR motif in folding and domain swapping of the HIV capsid protein C-terminal domain.
    Bocanegra R; Fuertes MÁ; Rodríguez-Huete A; Neira JL; Mateu MG
    Biophys J; 2015 Jan; 108(2):338-49. PubMed ID: 25606682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.